Goodbody Health (AQSE: GDBY) is pleased to announce that, following the UK Food Standard Agencies (FSA) publication of the Novel Foods approved list for CBD, the Company’s application has been authorised by the FSA to the next stage of the Novel Foods submission, being the publication of the Awaiting Evidence List. This means the FSA are now awaiting the final toxicology results and are satisfied with all the other evidence submitted. Once received, and if successful, the Company will progress onto the final Validated list.